Print Page   |   Contact Us   |   Your Cart   |   Report Abuse   |   Sign In   |   Apply for NAQC Membership
Site Search
Sign up for NAQC membership today!

Receive a monthly issue of Connections!
NAQC Newsroom: Tobacco Control

FDA Actions Related to Nicotine Replacement Therapies and Smoking-Cessation Products

Wednesday, December 12, 2012  
Posted by: Natalia Gromov
The Food and Drug Administration (FDA) has announced a 1-day public hearing, "FDA Actions Related to Nicotine Replacement Therapies and Smoking-Cessation Products; Report to Congress on Innovative Products and Treatments for Tobacco Dependence,” on December 17, 2012.

FDA is interested in obtaining input on certain questions related to the implementation of section 918 of the Food, Drug, and Cosmetics Act, a provision that was added by the Family Smoking Prevention and Tobacco Control Act of 2009.

Topics on which input is sought include applicable approval mechanisms and additional indications for nicotine replacement therapies (NRTs), and the regulation and development of innovative products and treatments for tobacco dependence.

FDA is seeking input from interested stakeholders, including manufacturers, industry and professional organizations, the public health community, individuals affected by tobacco dependence, researchers, health care professionals, and the public. Attendance is free and will be on a first-come, first-served basis. Individuals who wish to present at the public hearing must register by December 6, 2012, and provide complete contact information, including name, title, affiliation, address, email, and phone number to: Section918PublicMeeting@fda.hhs.gov .

Please find additional meeting details in the FederalRegister notice: http://www.regulations.gov/#!documentDetail;D=FDA-2012-N-1148-0001

Sign In


Forgot your password?

Not a NAQC Member?

Latest News

Membership 11 years!.

    3219 E. Camelback Road, #416, Phoenix, AZ 85018 | Ph: 800.398.5489 | Fax: 800.398.5489 | email: naqc@naquitline.org